E M van der Steen-Banasik
Overview
Explore the profile of E M van der Steen-Banasik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
554
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van den Heerik A, Aiyer K, Stelloo E, Jurgenliemk-Schulz I, Lutgens L, Jobsen J, et al.
Gynecol Oncol
. 2022 Jul;
166(3):530-537.
PMID: 35840357
Objective: Microcystic, elongated fragmented (MELF) pattern of myometrial invasion is a distinct histologic feature occasionally seen in low-grade endometrial carcinomas (EC). The prognostic relevance of MELF invasion was uncertain due...
2.
Wortman B, Astreinidou E, Laman M, van der Steen-Banasik E, Lutgens L, Westerveld H, et al.
Radiother Oncol
. 2020 Nov;
155:160-166.
PMID: 33159971
Objective: The PORTEC-4a trial investigates molecular-integrated risk profile guided adjuvant treatment for endometrial cancer. The quality assurance programme included a dummy run for vaginal brachytherapy prior to site activation, and...
3.
Wortman B, Creutzberg C, Putter H, Jurgenliemk-Schulz I, Jobsen J, Lutgens L, et al.
Br J Cancer
. 2018 Oct;
119(9):1067-1074.
PMID: 30356126
Background: PORTEC-2 was a randomised trial for women with high-intermediate risk (HIR) endometrial cancer, comparing pelvic external beam radiotherapy (EBRT) with vaginal brachytherapy (VBT). We evaluated long-term outcomes combined with...
4.
Wortman B, Bosse T, Nout R, Lutgens L, van der Steen-Banasik E, Westerveld H, et al.
Gynecol Oncol
. 2018 Aug;
151(1):69-75.
PMID: 30078506
Objective: The Post-Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-4a trial is a randomized trial for women with high-intermediate risk endometrial cancer (EC), comparing individualized adjuvant treatment based on a molecular-integrated...
5.
Bus S, Leus N, Oosterveld B, Van Gellekom M, van de Loop G, van der Steen-Banasik E
Brachytherapy
. 2017 Mar;
17(1):24-30.
PMID: 28274757
Purpose: The goal of this study was to verify the position of catheters used over 4 days for brachytherapy of solitary bladder tumors. Methods And Materials: The study covered three...
6.
Geels Y, van der Putten L, van der Steen-Banasik E, Snijders M, Massuger L, Pijnenborg J
Eur J Gynaecol Oncol
. 2015 Sep;
36(4):402-5.
PMID: 26390691
Purpose Of Investigation: There is no consensus on the management of Stage I endometrioid endometrial cancer (EEC) with grade 3 histology. This study evaluates the opinion of gynecologists in The...
7.
Nout R, Smit V, Putter H, Jurgenliemk-Schulz I, Jobsen J, Lutgens L, et al.
Lancet
. 2010 Mar;
375(9717):816-23.
PMID: 20206777
Background: After surgery for intermediate-risk endometrial carcinoma, the vagina is the most frequent site of recurrence. This study established whether vaginal brachytherapy (VBT) is as effective as pelvic external beam...
8.
Matzinger O, Duclos F, Van den Bergh A, Carrie C, Villa S, Kitsios P, et al.
Eur J Cancer
. 2009 Aug;
45(16):2825-34.
PMID: 19682889
Introduction: This trial randomly assessed short-term adjuvant hormonal therapy added to radiotherapy (RT) for intermediate- and high-risk (UICC 1997 cT2a or cT1b-c with high PSA or Gleason score) localised prostate...
9.
Matzinger O, Roelofsen F, Mineur L, Koswig S, van der Steen-Banasik E, Van Houtte P, et al.
Eur J Cancer
. 2009 Aug;
45(16):2782-91.
PMID: 19643599
Purpose: To assess the feasibility and activity of radio-chemotherapy with mitomycin C (MMC) and cisplatin (CDDP) in locally advanced squamous cell anal carcinoma with reference to radiotherapy (RT) combined with...
10.
Jobsen J, Lybeert M, van der Steen-Banasik E, Slot A, van der Palen J, Ten Cate L, et al.
Int J Gynecol Cancer
. 2007 Dec;
18(5):1071-8.
PMID: 18081796
The aim of this study was to report outcome data and prognostic factors from a large cohort of pathologic stage II endometrioid type endometrial carcinoma. One hundred forty-two stage IIA-B...